Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 38 clinical trials
A Pilot Study Assessing Impulsivity in Patients With Huntington's Disease on Xenazine (Tetrabenazine)

The purpose of this research study is to see if tetrabenazine, which is commonly used to treat Huntington's Disease (HD), reduces the problems of impulsivity that are common in patients with HD. Investigators will also see how the medicine affects aspects of thinking and mood.

chorea
xenazine
tetrabenazine
  • 0 views
  • 23 Sep, 2022
  • 1 location
Safety and Efficacy of AMT-130 in European Adults With Early Manifest Huntington Disease

This is the second study of AMT-130 in patients with early manifest HD and is designed as part of an integrated two-study phase I/II program under a single data safety monitoring board (DSMB) with staggered enrollment based upon continued demonstration of safety of AMT-130 administration.

htt gene
  • 0 views
  • 21 Mar, 2022
  • 1 location
Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease

Examine the effects of deutetrabenazine on functional speech and gait impairment

cognitive assessment
  • 1 views
  • 24 Jan, 2022
  • 1 location
TEsting METformin Against Cognitive Decline in HD

Multicenter, randomized, double-blind, placebo-controlled, parallel group study to assess the efficacy and safety of metformin treatment at a dose of 1700 mg / day in adults with Huntington's disease. The study consists of a screening period (2 to 4 weeks), followed by a 52-week double-blind treatment period and a follow-up …

cognitive decline
  • 0 views
  • 23 Apr, 2022
  • 7 locations
Safety and Proof-of-Concept (POC) Study With AMT-130 in Adults With Early Manifest Huntington Disease

This is the first study of AMT-130 in patients with early manifest HD and is designed to establish safety and proof-of-concept (PoC). CT-AMT-130-01 is a Phase I/II, randomized, multicenter, dose escalation, double-blind, imitation surgery, first-in-human (FIH) study.

chorea
htt gene
  • 162 views
  • 17 Feb, 2022
  • 12 locations
Study of BDNF Pathway Biomarkers in the Cerebrospinal Fluid in Patients With Huntington's Disease (LCR-MH)

Huntington disease (HD, 1.3/10 000) is an autosomal dominant disease due to an abnormal expansion of CAG triplets in HTT gene. Several pathophysiological mechanisms have been evoked, including an alteration of the signaling pathway of the Brain Derived Neurotrophic Factor (BDNF), a neurotrophic factor involved in the survival of neurons …

chorea
htt gene
Accepts healthy volunteers
autosomal dominant
  • 0 views
  • 04 Mar, 2022
  • 1 location
A Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's Disease

The primary purpose of this study is to evaluate the effect of SAGE-718 on cognitive performance and functioning in participants with HD.

cognitive assessment
  • 2 views
  • 16 Sep, 2022
  • 12 locations
Phase IIb, Randomized, Double-blind, Placebo-controlled Study in Parallel Groups Assessing the Efficacy and Safety of Two Doses of SOM3355 in Patients Suffering From Huntington's Disease With Choreic Movements

Phase IIb, randomized, double-blind, placebo-controlled study in parallel groups assessing the efficacy and safety of two doses of SOM3355 in patients suffering from Huntington's Disease with choreic movements.

htt gene
  • 0 views
  • 19 Sep, 2022
  • 4 locations
A Study to Evaluate the Effect of SAGE-718 on Functioning Capacity in Participants With Huntington's Disease

The primary purpose of this study is to assess the magnitude of the baseline difference between participants with early Huntington's Disease (HD) and healthy participants (HP) with respect to measures of cognitive performance and the effect of SAGE-718 on cognitive performance and functioning in participants with HD.

cognitive impairment
Accepts healthy volunteers
cognitive assessment
  • 0 views
  • 04 Oct, 2022
  • 1 location
iMagemHTT: FIH Evaluation of Novel Mutant Huntingtin PET Radioligands [¹¹C]CHDI-00485180-R and [¹¹C]CHDI-00485626

This is a FIH (first-in-human) adaptive PET (Positron Emission Tomography) imaging study to explore the binding and kinetic properties of two potential mutant huntingtin (mHTT) radioligands; [C]CHDI-00485180-R and [C]CHDI-00485626. The binding characteristics of these radioligands will be evaluated first in young (< 35 years of age) healthy control (HC) participants …

Accepts healthy volunteers
body mass index
  • 0 views
  • 04 Oct, 2022
  • 1 location